Midterm outcomes of mitral valve replacement in children: a retrospective study

Objective This study aimed to evaluate the midterm outcomes of mitral valve replacement (MVR) in children aged 1–18 years with irreparable mitral valve disease. Methods We conducted a retrospective analysis of patients who underwent MVR at our institution between January 2010 and December 2025. We excluded patients who underwent valve repair or were outside the age range. We collected and analyzed preoperative, intraoperative, postoperative, and follow-up data for the enrolled pediatric patients. Results A total of 89 patients were enrolled in this study, including 41 males and 48 females, with a median age of 9.0 years (IQR 4.0–14.0). Median weight and body surface area were 24.8 kg (IQR 13.5, 38.6) and 0.9 m 2 (IQR 0.6–1.3), respectively. The preoperative diagnoses included mitral stenosis in 31 patients (34.8%), mitral regurgitation in 78 patients (87.6%), and combined mitral stenosis and regurgitation in 20 patients (22.5%). A subset of patients had associated anomalies, including complete atrioventricular septal defect, partial anomalous pulmonary venous connection, and congenital mitral valve malformations. All 89 patients successfully underwent the procedure. The operative time was 310.3 ± 96.4 min, cardiopulmonary bypass time was 177.2 ± 72.5 min, and aortic cross-clamp time was 102.5 ± 44.3 min. Postoperative mechanical ventilation duration was 21.0 h (IQR 10.0–36.9), ICU stay was 3.0 days (IQR 2.0–6.3), and hospital length of stay was 26.0 days (IQR 18.8–37.5). A total of 34 patients (38.2%) underwent implantation with a 25# valve, 24 patients (27.0%) with a 27# valve, and 11 patients (12.4%) with a 23# valve. At a median follow-up of 24.5 months (IQR 7.0, 69.0), crude overall survival was 98.9% (88/89). Conclusion MVR represents a feasible and safe treatment strategy for children with irreparable mitral valve lesions, demonstrating excellent midterm survival and low complication rates in this cohort.

Authors

Institutions

Publication Details

Journal
Frontiers in Pediatrics
Published
2026-11-13
DOI
https://doi.org/10.3389/fped.2026.1959948
Primary Topic
Cardiac Valve Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Midterm outcomes of mitral valve replacement in children: a retrospective study

Rixin Liang, Jing Ling, Shusheng Wen, Jiaxiong Wu et al.
1 links
Frontiers in Pediatrics
Cardiac Valve Diseases and Treatments
article

Midterm outcomes of mitral valve replacement in children: a retrospective study

Rixin Liang, Jing Ling, Shusheng Wen, Jiaxiong Wu, Jinxin Li, Haiyun Yuan, Canxin Wang, Zirui Peng
article en

Abstract

Objective This study aimed to evaluate the midterm outcomes of mitral valve replacement (MVR) in children aged 1–18 years with irreparable mitral valve disease. Methods We conducted a retrospective analysis of patients who underwent MVR at our institution between January 2010 and December 2025. We excluded patients who underwent valve repair or were outside the age range. We collected and analyzed preoperative, intraoperative, postoperative, and follow-up data for the enrolled pediatric patients. Results A total of 89 patients were enrolled in this study, including 41 males and 48 females, with a median age of 9.0 years (IQR 4.0–14.0). Median weight and body surface area were 24.8 kg (IQR 13.5, 38.6) and 0.9 m 2 (IQR 0.6–1.3), respectively. The preoperative diagnoses included mitral stenosis in 31 patients (34.8%), mitral regurgitation in 78 patients (87.6%), and combined mitral stenosis and regurgitation in 20 patients (22.5%). A subset of patients had associated anomalies, including complete atrioventricular septal defect, partial anomalous pulmonary venous connection, and congenital mitral valve malformations. All 89 patients successfully underwent the procedure. The operative time was 310.3 ± 96.4 min, cardiopulmonary bypass time was 177.2 ± 72.5 min, and aortic cross-clamp time was 102.5 ± 44.3 min. Postoperative mechanical ventilation duration was 21.0 h (IQR 10.0–36.9), ICU stay was 3.0 days (IQR 2.0–6.3), and hospital length of stay was 26.0 days (IQR 18.8–37.5). A total of 34 patients (38.2%) underwent implantation with a 25# valve, 24 patients (27.0%) with a 27# valve, and 11 patients (12.4%) with a 23# valve. At a median follow-up of 24.5 months (IQR 7.0, 69.0), crude overall survival was 98.9% (88/89). Conclusion MVR represents a feasible and safe treatment strategy for children with irreparable mitral valve lesions, demonstrating excellent midterm survival and low complication rates in this cohort.

Frontiers in PediatricsVol. 14
Guangdong Academy of Medical Sciences (CN), Guangdong Provincial People's Hospital (CN), Southern Medical University (CN)
Good health and well-being
Cardiac Valve Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon